Harnessing Oncolytic Virus-mediated Anti-tumour Immunity

Treatment of permissive tumours with the oncolytic virus (OV) VSV-Δ51 leads to a robust anti-tumour T cell response, which contributes to efficacy; however, many tumours are not permissive to in vivo treatment with VSV-Δ51. In an attempt to channel the immune stimulatory properties of VSV-Δ51 and br...

Full description

Bibliographic Details
Main Author: Lemay, Chantal
Other Authors: Bell, John
Language:en
Published: Université d'Ottawa / University of Ottawa 2012
Subjects:
Online Access:http://hdl.handle.net/10393/23318
http://dx.doi.org/10.20381/ruor-2918